Orchid Pharma Limited — Board Meeting, 25-05-2026: Outcome of Board Meeting

Orchid Pharma's board approved Q4 & FY26 consolidated results: FY26 profit at ₹20.55 Cr, Q4 profit at ₹23.78 Cr. Key moves: completed Allecra Therapeutics acquisition for global rights to antibiotic Enmetazobactam. Amalgamation with Dhanuka Labs awaits NCLT order. New internal auditor appointed.